search
Back to results

Safety and Efficacy of Sofwave Treatment for Acne Scars Appearance Improvement

Primary Purpose

Acne Scars - Mixed Atrophic and Hypertrophic

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Sofwave
Sponsored by
Sofwave Medical LTD
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Acne Scars - Mixed Atrophic and Hypertrophic focused on measuring Acne Scars

Eligibility Criteria

22 Years - 80 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Healthy male or female subjects > 22 years of age and < 80 years of age.
  2. For female subjects, not pregnant or lactating and must be either post-menopausal, surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment (i.e., oral contraceptives, contraceptive implant, barrier methods with spermicide) or abstinence.
  3. Seeking treatment for facial acne scars.
  4. Have visible mild to moderate facial acne scars.
  5. Agree not to undergo any other facial acne scars treatments for a period of 3 months following Sofwave treatments.
  6. Willing to have photographs of the treated areas. Agree for de-identified study images to be used in evaluations, publications and presentations.
  7. Able and willing to comply with all visits, treatments and evaluations schedules and requirements.
  8. Able to understand and provide written Informed Consent

Exclusion Criteria:

  1. Pregnant or planning to become pregnant during the duration of the study, having given birth less than 3 months ago, and/or breast feeding
  2. Current smoker or has history of heavy smoking (25 cigarettes per day or more) in past 10 years.
  3. History of severe migraine tendency.
  4. History of Epileptic seizures.
  5. History of chronic drug or alcohol abuse.
  6. Taking Isotretinoin or other oral retinoid within the past 6 months; taking anti-platelet or anti-coagulant within the past 2 weeks.
  7. Medical disorder that may hinder the wound healing or immune response (such as blood disorder, inflammatory disease, etc.)
  8. Presence of a metal stent or implant in the facial area.
  9. Known allergy to tetracaine, Xylocaine or epinephrine.
  10. Active malignancy or history of malignancy in the past 5 years.
  11. Suffering from significant concurrent illness, such as cardiac disorders, diabetes (type I or II), lupus, porphyria, or pertinent neurological disorders (i.e. any disease state that in the opinion of the investigator may interfere with the anesthesia, treatment, or healing process).
  12. History of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or currently using immunosuppressive medications.
  13. Presence of any active systemic or local infections.
  14. Severe or cystic facial acne, acutance uses during past 6 months.
  15. History of cosmetic treatments in the facial area to be treated, including facial skin-tightening procedure within the 6 months; injectable (Botox or fillers of any type) within the 6 months; ablative or non-ablative resurfacing/rejuvenation laser treatment or light treatment within the past 6 months, dermabrasion or deep facial peels within the past 12 months; facelift or blepharoplasty within the past 12 months.
  16. Inability to understand the protocol or to give informed consent
  17. On-going use of psychiatric medication
  18. Unable or unwilling to comply with the study requirements and procedures
  19. Currently enrolled in a clinical study of any other unapproved investigational drug or device
  20. As per the investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.

Sites / Locations

  • SLSS, a Division of Schweiger Dermatology Group Research OfficeRecruiting
  • UnionDermRecruiting
  • Laser & Skin Surgery Center of New York®Recruiting
  • New York Laser & Skin Care

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Acne Scars

Arm Description

Outcomes

Primary Outcome Measures

Rate of change of acne scars appearance, as assessed by independent masked evaluators at 3 months post last treatment session.
following Sofwave treatments based on 6 points simplified Acne Severity Scale (ASS), as evaluated by independent masked reviewers.

Secondary Outcome Measures

Full Information

First Posted
April 27, 2022
Last Updated
April 10, 2023
Sponsor
Sofwave Medical LTD
search

1. Study Identification

Unique Protocol Identification Number
NCT05358860
Brief Title
Safety and Efficacy of Sofwave Treatment for Acne Scars Appearance Improvement
Official Title
Safety and Efficacy of Sofwave Treatment for Acne Scars Appearance Improvement
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Recruiting
Study Start Date
February 1, 2022 (Actual)
Primary Completion Date
September 10, 2023 (Anticipated)
Study Completion Date
September 10, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sofwave Medical LTD

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Open-label, non-randomized, prospective, multi-center, self-controlled clinical study with masked evaluation.
Detailed Description
Eligible patients will receive 3 treatments (4-6 weeks apart) on the facial acne scars using Sofwave System. Treatment may be administered after the enrollment and screening at the first visit, or it may occur later following the enrollment and screening activities based on site scheduling availabilities. All patients will return to the clinic for one follow up visit at 3 months ± 3 weeks post last treatment (FU1). Methodology described in the protocol to evaluate efficacy and safety of treatments will be carried out at each visit at the clinic.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acne Scars - Mixed Atrophic and Hypertrophic
Keywords
Acne Scars

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Acne Scars
Arm Type
Experimental
Intervention Type
Device
Intervention Name(s)
Sofwave
Other Intervention Name(s)
SUPERB
Intervention Description
The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.
Primary Outcome Measure Information:
Title
Rate of change of acne scars appearance, as assessed by independent masked evaluators at 3 months post last treatment session.
Description
following Sofwave treatments based on 6 points simplified Acne Severity Scale (ASS), as evaluated by independent masked reviewers.
Time Frame
1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
22 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy male or female subjects > 22 years of age and < 80 years of age. For female subjects, not pregnant or lactating and must be either post-menopausal, surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment (i.e., oral contraceptives, contraceptive implant, barrier methods with spermicide) or abstinence. Seeking treatment for facial acne scars. Have visible mild to moderate facial acne scars. Agree not to undergo any other facial acne scars treatments for a period of 3 months following Sofwave treatments. Willing to have photographs of the treated areas. Agree for de-identified study images to be used in evaluations, publications and presentations. Able and willing to comply with all visits, treatments and evaluations schedules and requirements. Able to understand and provide written Informed Consent Exclusion Criteria: Pregnant or planning to become pregnant during the duration of the study, having given birth less than 3 months ago, and/or breast feeding Current smoker or has history of heavy smoking (25 cigarettes per day or more) in past 10 years. History of severe migraine tendency. History of Epileptic seizures. History of chronic drug or alcohol abuse. Taking Isotretinoin or other oral retinoid within the past 6 months; taking anti-platelet or anti-coagulant within the past 2 weeks. Medical disorder that may hinder the wound healing or immune response (such as blood disorder, inflammatory disease, etc.) Presence of a metal stent or implant in the facial area. Known allergy to tetracaine, Xylocaine or epinephrine. Active malignancy or history of malignancy in the past 5 years. Suffering from significant concurrent illness, such as cardiac disorders, diabetes (type I or II), lupus, porphyria, or pertinent neurological disorders (i.e. any disease state that in the opinion of the investigator may interfere with the anesthesia, treatment, or healing process). History of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or currently using immunosuppressive medications. Presence of any active systemic or local infections. Severe or cystic facial acne, acutance uses during past 6 months. History of cosmetic treatments in the facial area to be treated, including facial skin-tightening procedure within the 6 months; injectable (Botox or fillers of any type) within the 6 months; ablative or non-ablative resurfacing/rejuvenation laser treatment or light treatment within the past 6 months, dermabrasion or deep facial peels within the past 12 months; facelift or blepharoplasty within the past 12 months. Inability to understand the protocol or to give informed consent On-going use of psychiatric medication Unable or unwilling to comply with the study requirements and procedures Currently enrolled in a clinical study of any other unapproved investigational drug or device As per the investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Shlomit Mann, MSc
Phone
+97247800268
Email
Shlomit@sofwave.com
First Name & Middle Initial & Last Name or Official Title & Degree
Ruthie Amir, MD
Phone
+97243003164
Email
Ruthie@sofwave.com
Facility Information:
Facility Name
SLSS, a Division of Schweiger Dermatology Group Research Office
City
Hackensack
State/Province
New Jersey
ZIP/Postal Code
07601
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Diana Aranzazu
Phone
201-951-0701
Email
dianaa@skinandlasers.com
First Name & Middle Initial & Last Name & Degree
David Goldberg, MD
First Name & Middle Initial & Last Name & Degree
Amy Tank, PA
Facility Name
UnionDerm
City
New York
State/Province
New York
ZIP/Postal Code
10003
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Danielle Robinson
Phone
212-366-5400
Email
research@unionderm.com
First Name & Middle Initial & Last Name & Degree
Anne M. Chapas, MD
Facility Name
Laser & Skin Surgery Center of New York®
City
New York
State/Province
New York
ZIP/Postal Code
10016
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jennifer Moreno
Phone
212-686-7306
Email
mail@laserskinsurgery.com
First Name & Middle Initial & Last Name & Degree
Roy Geronemus, MD
Facility Name
New York Laser & Skin Care
City
New York
State/Province
New York
ZIP/Postal Code
10028
Country
United States
Individual Site Status
Enrolling by invitation

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Safety and Efficacy of Sofwave Treatment for Acne Scars Appearance Improvement

We'll reach out to this number within 24 hrs